BOSTON, April 27, 2004 -- (PRIMEZONE)
-- NeuroSystems, LLC announced today that it will exhibit its intelligent multimodality
neurosurgical critical care monitoring system at the annual meeting of the American
Association of Neurological Surgeons (AANS), May 3-5 in Orlando.
The company's first product, NeuroSystems 1™, has been
designed to enable and accelerate what the company views as two parallel and interdependent
trends: the incorporation of multiple parameters into the regime of neurotrauma
and cerebrovascular disease critical care monitoring, and the consolidation of
an assortment of individual stand-alone monitors into one comprehensive, intelligent
bedside display.
Basic intracranial pressure (ICP) monitoring, though presently
the standard of care, is a rather late stage indicator of a patient's status and
probable clinical outcome. New sensor technologies which permit the monitoring
of other important physical and chemical quantities, including cerebral blood
flow (CBF), tissue oxygen and carbon dioxide, pH and brain temperature, have the
potential to improve management and outcomes. However, their acceptance has been
impeded both by a lack of consensus regarding the clinical significance of any
one parameter, and by an inability to monitor the relationships between and among
multiple parameters.
"The key to advancing multimodality
neuro monitoring is clinical utility," said Sean Maher, NeuroSystems' Chief
Operating Officer, "and the key to clinical utility is the ability to display
clinically useful higher order relationships between individual data. For example,
monitoring cerebral autoregulation is more useful than just looking at separate
measurements of cerebral blood flow and arterial pressure. Data in isolation is
not enough."
By intelligently blending various individual parameters, NeuroSystems 1 will provide
neurosurgeons and other clinicians the ability to monitor higher order, clinically
useful neurophysiologic functions including cerebral autoregulation, vasoreactivity
and oxygen metabolism, continuously and in real-time, via a series of full-featured
clinician displays.
"We are very excited about enabling a long-overdue multimodality
revolution in neurosurgical critical care monitoring, and we are moving rapidly
toward market introduction," commented Rick Cataldo, NeuroSystems' President.
"The AANS is our first exhibit at a major meeting, and a very important milestone
for the company."
NeuroSystems' mission is to develop and market intelligent NeuroMonitoring systems
which maximize the clinical value of basic monitored parameters through real-time
calculation, storage and display of clinically relevant derived parameters and
neurophysiologic indicators.
* CAUTION: Investigational Device. Limited by Federal (USA) law to investigational
use.
# # #
